Cargando…

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin

Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ong, Voon, Hough, Grayson, Schlosser, Michael, Bartizal, Ken, Balkovec, James M., James, Kenneth D., Krishnan, B. Radha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2016
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075098/ https://www.ncbi.nlm.nih.gov/pubmed/27620474 http://dx.doi.org/10.1128/AAC.00701-16

Ejemplares similares

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
por: Ong, Voon, et al.
Publicado: (2017)

CD101: a novel long‐acting echinocandin
por: Zhao, Yanan, et al.
Publicado: (2016)

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
por: Sandison, Taylor, et al.
Publicado: (2017)

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
por: James, Kenneth D., et al.
Publicado: (2017)

Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
por: Locke, Jeffrey B., et al.
Publicado: (2016)

In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis
por: Boikov, Dina A., et al.
Publicado: (2017)

CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms
por: Chandra, Jyotsna, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
por: Lakota, Elizabeth A., et al.
Publicado: (2017)

1283. New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single
por: Ong, Voon, et al.
Publicado: (2020)

Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model
por: Zhao, Yanan, et al.
Publicado: (2017)

Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants
por: Cheung, Yuk-Yam, et al.
Publicado: (2017)

Echinocandins Accelerate Particle Transport Velocity in the Murine Tracheal Epithelium: Dependency on Intracellular Ca(2+) Stores
por: Müller, Sabrina, et al.
Publicado: (2021)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1
por: Park, A. Young J., et al.
Publicado: (2022)

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
por: Pfaller, Michael A., et al.
Publicado: (2016)

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
por: Zhao, Yanan, et al.
Publicado: (2018)

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species
por: Locke, Jeffrey B., et al.
Publicado: (2018)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis
por: Hager, Christopher, et al.
Publicado: (2017)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101
por: Ohana, G, et al.
Publicado: (2003)

Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives
por: Padia, Janak, et al.
Publicado: (2020)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects
por: Eckburg, Paul B., et al.
Publicado: (2019)

Comparison of echinocandin antifungals
por: Eschenauer, Gregory, et al.
Publicado: (2007)

Fungal echinocandin resistance
por: Walker, Louise A., et al.
Publicado: (2010)

Fungal echinocandin resistance
por: Munro, Carol A
Publicado: (2010)

Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
por: Re, D, et al.
Publicado: (2002)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

Photodynamic diagnosis of ovarian cancer using hexaminolaevulinate: a preclinical study
por: Lüdicke, F, et al.
Publicado: (2003)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e96lb4vgpcqfbot72dqrf03bt4